• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

SF-6D 效用指数作为衡量健康状况变化的最小重要差异的指标。

SF-6D utility index as measure of minimally important difference in health status change.

机构信息

College of Pharmacy, University of Florida, Gainesville, USA.

出版信息

J Am Pharm Assoc (2003). 2012 Jan-Feb;52(1):34-42. doi: 10.1331/JAPhA.2012.10114.

DOI:10.1331/JAPhA.2012.10114
PMID:22257614
Abstract

OBJECTIVES

To combine anchor- and distribution-based approaches to identify minimally important differences (MIDs) for the short-form six-dimension utility index (SF-6D) and to identify variables associated with self-reported health status change.

DESIGN

Descriptive, exploratory, nonexperimental study.

SETTING

United States between April 1, 1999, and October 31, 1999.

PATIENTS

2,317 participants of SADD-Sx (Study of Antihypertensive Drugs and Depressive Symptoms), aged 50 years or older and with hypertension and coronary artery disease.

INTERVENTION

Patients were randomized into a verapamil SR- or atenolol-led hypertensive treatment strategy and mailed baseline and 1-year surveys.

MAIN OUTCOME MEASURE

SF-6D utility scores for patients completing both surveys.

RESULTS

The pooled mean (±SD) MID change on the SF-6D of patients whose health status minimally changed was 0.035 ± 0.095. The anchor-based change scores had a median value of 0.036 (interquartile range -0.03 to 0.10). One-third and one-half of the SD of SF-6D change scores were 0.035 and 0.053, respectively. Whites were less likely to report minimally improved health status compared with nonwhites (odds ratio 0.59 [95% CI 0.40-0.88]). Change in SF-6D scores improved prediction of health status change.

CONCLUSION

We recommend using the MID range based on all patients combined (-0.03 to 0.10) to interpret SF-6D scores. These estimates can be used in conjunction with other measures of efficacy to determine meaningful changes. SF-6D demonstrates potential utility in predicting minimally important improvement or worsening among patients receiving different pharmacologic medications.

摘要

目的

结合锚定和分布方法来确定简短六维度健康状况量表(SF-6D)的最小重要差异(MID),并确定与自我报告健康状况变化相关的变量。

设计

描述性、探索性、非实验研究。

地点

1999 年 4 月 1 日至 1999 年 10 月 31 日期间的美国。

患者

年龄在 50 岁或以上、患有高血压和冠心病的 SADD-Sx(抗高血压药物和抑郁症状研究)的 2317 名参与者。

干预

患者被随机分为维拉帕米 SR 或阿替洛尔主导的高血压治疗策略,并邮寄基线和 1 年调查。

主要观察指标

完成两次调查的患者的 SF-6D 效用评分。

结果

健康状况最小变化的患者 SF-6D 的平均(±SD)MID 变化为 0.035±0.095。基于锚定的变化评分中位数为 0.036(四分位距-0.03 至 0.10)。SF-6D 变化评分的三分之一和一半标准差分别为 0.035 和 0.053。与非白人相比,白人报告健康状况略有改善的可能性较小(比值比 0.59[95%置信区间 0.40-0.88])。SF-6D 评分的变化改善了健康状况变化的预测。

结论

我们建议使用基于所有患者的 MID 范围(-0.03 至 0.10)来解释 SF-6D 评分。这些估计值可以与其他疗效衡量标准一起使用,以确定有意义的变化。SF-6D 在预测接受不同药物治疗的患者中最小重要改善或恶化方面具有潜在的效用。

相似文献

1
SF-6D utility index as measure of minimally important difference in health status change.SF-6D 效用指数作为衡量健康状况变化的最小重要差异的指标。
J Am Pharm Assoc (2003). 2012 Jan-Feb;52(1):34-42. doi: 10.1331/JAPhA.2012.10114.
2
A Study of Antihypertensive Drugs and Depressive Symptoms (SADD-Sx) in patients treated with a calcium antagonist versus an atenolol hypertension Treatment Strategy in the International Verapamil SR-Trandolapril Study (INVEST).国际维拉帕米缓释片-群多普利研究(INVEST)中钙拮抗剂与阿替洛尔高血压治疗策略治疗患者的抗高血压药物与抑郁症状研究(SADD-Sx)
Psychosom Med. 2005 May-Jun;67(3):398-406. doi: 10.1097/01.psy.0000160468.69451.7f.
3
What is the relationship between the minimally important difference and health state utility values? The case of the SF-6D.最小重要差异与健康状态效用值之间的关系是什么?以SF-6D为例。
Health Qual Life Outcomes. 2003 Apr 11;1:4. doi: 10.1186/1477-7525-1-4.
4
Comparison of the minimally important difference for two health state utility measures: EQ-5D and SF-6D.两种健康状态效用测量方法(EQ-5D和SF-6D)最小重要差异的比较。
Qual Life Res. 2005 Aug;14(6):1523-32. doi: 10.1007/s11136-004-7713-0.
5
A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial.钙拮抗剂与非钙拮抗剂治疗冠心病患者高血压的策略。国际维拉帕米-群多普利研究(INVEST):一项随机对照试验。
JAMA. 2003 Dec 3;290(21):2805-16. doi: 10.1001/jama.290.21.2805.
6
Estimation of minimally important differences in the EQ-5D and SF-6D indices and their utility in stroke.EQ-5D和SF-6D指数中最小重要差异的估计及其在中风中的应用。
Health Qual Life Outcomes. 2015 Mar 9;13:32. doi: 10.1186/s12955-015-0227-3.
7
A comparison of utility measurement using EQ-5D and SF-6D preference-based generic instruments in patients with rheumatoid arthritis.类风湿关节炎患者使用 EQ-5D 和 SF-6D 偏好型通用量表进行效用测量的比较。
Clin Exp Rheumatol. 2011 Jul-Aug;29(4):661-71. Epub 2011 Aug 31.
8
Validity and responsiveness of EQ-5D-5L and SF-6D in patients with health complaints attributed to their amalgam fillings: a prospective cohort study of patients undergoing amalgam removal.健康抱怨归因于银汞合金填充物的患者中 EQ-5D-5L 和 SF-6D 的有效性和反应度:接受银汞合金去除术的患者的前瞻性队列研究。
Health Qual Life Outcomes. 2021 Apr 17;19(1):125. doi: 10.1186/s12955-021-01762-4.
9
Effects of verapamil SR and atenolol on 24-hour blood pressure and heart rate in hypertension patients with coronary artery disease: an international verapamil SR-trandolapril ambulatory monitoring substudy.缓释维拉帕米和阿替洛尔对冠心病高血压患者24小时血压和心率的影响:一项国际缓释维拉帕米-群多普利动态监测子研究
PLoS One. 2015 Apr 2;10(4):e0122726. doi: 10.1371/journal.pone.0122726. eCollection 2015.
10
Clinical outcomes in the diabetes cohort of the INternational VErapamil SR-Trandolapril study.国际维拉帕米缓释片-群多普利研究糖尿病队列的临床结局
Hypertension. 2004 Nov;44(5):637-42. doi: 10.1161/01.HYP.0000143851.23721.26. Epub 2004 Sep 20.

引用本文的文献

1
A systematic review of minimum important changes for generic multi-attribute utility instruments and recommendations for their estimation.通用多属性效用工具最小重要变化的系统评价及其估计建议。
Eur J Health Econ. 2025 Apr 16. doi: 10.1007/s10198-025-01778-3.
2
Association of Health-Related Quality of Life with Overall Survival in Older Americans with Kidney Cancer: A Population-Based Cohort Study.美国老年肾癌患者健康相关生活质量与总生存期的关联:一项基于人群的队列研究。
Healthcare (Basel). 2021 Oct 10;9(10):1344. doi: 10.3390/healthcare9101344.
3
Within-Trial Cost-Effectiveness of a Structured Lifestyle Intervention in Adults With Overweight/Obesity and Type 2 Diabetes: Results From the Action for Health in Diabetes (Look AHEAD) Study.
超重/肥胖和 2 型糖尿病成人中结构化生活方式干预的试验内成本效益:来自糖尿病行动研究(Look AHEAD)的结果。
Diabetes Care. 2021 Jan;44(1):67-74. doi: 10.2337/dc20-0358. Epub 2020 Nov 9.
4
Quality of Life in Palliative Care.姑息治疗中的生活质量
Expert Rev Qual Life Cancer Care. 2017;2(6):293-302. doi: 10.1080/23809000.2017.1400911. Epub 2017 Nov 8.
5
Models for Predicting Recurrence, Complications, and Health Status in Women After Pelvic Organ Prolapse Surgery.预测女性盆腔器官脱垂手术后复发、并发症和健康状况的模型。
Obstet Gynecol. 2018 Aug;132(2):298-309. doi: 10.1097/AOG.0000000000002750.
6
Impact of intensive lifestyle intervention on preference-based quality of life in type 2 diabetes: Results from the Look AHEAD trial.强化生活方式干预对2型糖尿病患者基于偏好的生活质量的影响:Look AHEAD试验结果
Obesity (Silver Spring). 2016 Apr;24(4):856-64. doi: 10.1002/oby.21445. Epub 2016 Mar 8.
7
Health-related quality of life in older adult survivors of selected cancers: data from the SEER-MHOS linkage.特定癌症老年成年幸存者的健康相关生活质量:来自监测、流行病学和最终结果-医疗保险受益数据系统(SEER-MHOS)关联研究的数据
Cancer. 2015 Mar 1;121(5):758-65. doi: 10.1002/cncr.29119. Epub 2014 Nov 4.